Illustrative of these advancements, a multimodal oncolytic HSV, expressing the shared TAA ephrin A2 (EphA2), elicits a potent acquired antitumor immune response in oncolytic HSV‐resistant murine brain and peripheral tumor models. This evidence concerns the gene EPHA2 and neoplasm.